# Arcutis Biotherapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Arcutis Biotherapeutics, Inc.).

## Overview

Arcutis Biotherapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on dermatology. Its core business is developing and selling treatments for immune-mediated skin diseases, with ZORYVE as its commercial product platform. The company combines in-house dermatology expertise with a development strategy centered on validated biological targets and differentiated topical and systemic therapies. Arcutis currently operates as a single-reportable-segment business and is building out its own U.S. and Canadian commercialization infrastructure.

## Products & services

• ZORYVE cream 0.3% for plaque psoriasis and other indications
• ZORYVE foam for seborrheic dermatitis and psoriasis
• ZORYVE cream 0.15% for atopic dermatitis
• Commercialization of dermatology products in the U.S. and Canada
• License/collaboration revenue from Sato and Huadong agreements
• Development of ARQ-234 and ARQ-255
• Label expansion programs for ZORYVE

- **Commercial dermatology products** (85%) — Prescription topical products sold under the ZORYVE brand for inflammatory skin diseases.
- **License and collaboration revenue** (10%) — Revenue from partnering agreements, primarily Sato and Huadong, tied to ex-U.S. development and commercialization rights.
- **Pipeline development programs** (5%) — Internal R&D programs for ARQ-234, ARQ-255, and additional ZORYVE label expansions.

- ZORYVE cream 0.3% topical treatment
- ZORYVE foam topical treatment
- ZORYVE cream 0.15% for atopic dermatitis
- Commercial sales and promotion in the U.S. and Canada
- License and collaboration arrangements with Sato and Huadong
- Clinical development of ARQ-234
- Clinical development of ARQ-255 and ZORYVE label extensions

## Customers

Arcutis sells primarily into the prescription dermatology channel, where dermatologists and allergists prescribe ZORYVE for immune-mediated skin conditions. In the U.S., the company also serves wholesalers and specialty pharmacies that distribute the product to end patients and manage chargebacks, inventory, and reporting. As the company expands into pediatric and primary care settings, it is targeting high-prescribing physicians who can broaden adoption beyond specialist dermatology. In Canada, Arcutis has built commercial infrastructure to support local product launches, while in Asia it relies on partners to reach additional markets.

- **Dermatologists** (primary) — Core prescribers for ZORYVE who treat plaque psoriasis, seborrheic dermatitis, and atopic dermatitis and value differentiated topical options.
- **Allergists** (primary) — Specialists who prescribe ZORYVE for immune-mediated dermatological conditions, especially atopic dermatitis.
- **Wholesalers and specialty pharmacies** (primary) — Distribution intermediaries that buy product for channel fulfillment, inventory management, and chargeback administration.
- **Primary care and pediatric providers** (secondary) — A growing target segment for ZORYVE expansion after the end of the Kowa promotion agreement.
- **International partners** (secondary) — Licensees and collaborators in Japan, China, and other Asian markets that commercialize roflumilast formulations locally.

- Dermatologists prescribing ZORYVE for inflammatory skin diseases
- Allergists treating patients with atopic dermatitis and related conditions
- Primary care and pediatric providers targeted for broader ZORYVE use
- Wholesalers and specialty pharmacies that distribute the product
- Patients with prescription dermatology needs, reached through prescribers
- International partners in Asia that commercialize roflumilast formulations

## Geography

Arcutis is headquartered in Westlake Village, California and conducts its main commercial operations in the United States. The company also has established commercialization infrastructure in Canada, where ZORYVE has been launched in multiple formulations and indications. Outside North America, Arcutis uses partnerships to access markets such as Japan, China, and other countries in Asia rather than building a full direct-sales footprint. Because the company relies on third-party manufacturing and distribution, its geographic exposure is shaped more by commercial launch timing and partner execution than by owned production assets.

- United States is the core commercial market and operating base
- Canada is an active second market with local commercialization infrastructure
- Asia is accessed mainly through licensing and collaboration partners
- Japan and China are specifically mentioned partner markets
- Westlake Village, California is the corporate headquarters
- No internal manufacturing footprint; supply is outsourced

## Strategy

Arcutis is prioritizing commercial execution for ZORYVE while continuing to expand the product's label and reach into additional dermatology settings. The company is shifting more selling responsibility into pediatric and primary care after the Kowa promotion agreement ends, which should broaden the prescriber base beyond dermatology specialists. At the same time, it is focusing clinical development on ARQ-234, ARQ-255, and additional ZORYVE label extensions to extend the franchise. Because Arcutis has no internal manufacturing, it also depends on third parties for supply and must manage partner quality, capacity, and continuity carefully.

- **Broaden ZORYVE prescribing beyond dermatology specialists** (short-term) — A wider prescriber base can increase product uptake and reduce dependence on a narrow specialist channel.
- **Advance pipeline and label expansions** (medium-term) — New indications and next-generation assets can extend the life of the franchise and diversify revenue.
- **Expand through partnerships outside North America** (medium-term) — Partnering allows Arcutis to access markets without building a full international commercial organization.

- Expand ZORYVE adoption in dermatology, pediatric, and primary care settings
- Advance ARQ-234 and ARQ-255 through clinical and regulatory milestones
- Pursue ZORYVE label extensions to widen the commercial franchise
- Maintain and grow U.S. and Canadian commercialization infrastructure
- Use partnerships to access Japan, China, and other Asian markets
- Rely on outsourced manufacturing and supply while scaling commercial demand

## Risks

Arcutis remains exposed to the execution risk typical of a commercial-stage biopharmaceutical company with a concentrated product base. Its revenue depends heavily on ZORYVE adoption, reimbursement, and competitive positioning, while generic, OTC, and branded prescription alternatives could pressure demand and pricing. The company also relies on third-party manufacturers, single-source suppliers, and external clinical vendors, so any supply disruption or quality issue could affect launches and product availability. In addition, the company continues to face losses, funding needs, cybersecurity risk, and the possibility that patent protection or litigation outcomes could weaken the franchise over time.

- **Concentration in a small number of commercial products** [high] — The company is still building its dermatology franchise, so ZORYVE performance is central to revenue and operating leverage.
- **Competitive pressure from existing and new dermatology therapies** [high] — Alternative prescription and OTC products can limit demand, pricing, and reimbursement for ZORYVE.
- **Patent and generic erosion risk** [critical] — Loss of patent protection or an at-risk generic launch could cause a rapid decline in sales of approved products.
- **Third-party manufacturing and supply dependence** [high] — The company has no internal manufacturing capabilities and relies on external suppliers for commercial and clinical supply.
- **Financing and liquidity risk** [high] — Continued commercialization and R&D spending may require additional capital if operating cash flow is insufficient.
- **Cybersecurity and data privacy incidents** [medium] — A breach could disrupt operations, damage intellectual property, and create remediation and notification costs.

- Dependence on ZORYVE commercialization and reimbursement
- Competition from branded, generic, and OTC dermatology treatments
- Patent expiry or at-risk generic launch could rapidly erode sales
- Reliance on third-party and single-source manufacturing suppliers
- Need to fund ongoing R&D and commercialization despite losses
- Cybersecurity and data privacy incidents could disrupt operations
- Partner execution risk in international licensing markets

## Accounting

Arcutis recognizes product revenue net of rebates, chargebacks, discounts, distribution service fees, and estimated returns, so launch timing and estimate updates can materially affect reported revenue. Because the company is still building product history, its reserves for sales returns and other deductions require judgment and can change as actual experience develops. Cost of sales includes third-party manufacturing, packaging, freight, royalties, and amortization of ZORYVE-related intangible assets, which means margin can shift as inventory previously expensed is sold and as royalty burdens change. The company also records significant R&D and SG&A accruals, and its tax accounting is affected by large deferred tax assets and valuation allowances tied to net operating losses and capitalized research costs.

- **Net product revenue deductions** — Can materially affect quarterly revenue and comparability
- **Sales return reserve estimation** — Affects net revenue and gross-to-net trends
- **Inventory and cost of sales timing** — Impacts gross margin and quarterly cost of sales
- **Deferred tax assets and valuation allowance** — Affects tax expense and balance sheet presentation

- Revenue is recorded net of rebates, chargebacks, discounts, and returns
- Sales return estimates can change as launch history becomes more established
- Distribution service fees reduce gross product revenue
- Cost of sales includes third-party manufacturing and royalties
- Amortization of ZORYVE-related intangible assets affects gross margin
- Deferred tax asset valuation allowance reflects accumulated losses and tax attributes
- No internal manufacturing means inventory and supply commitments require careful accruals

---

*Last updated: 2026-08-11T04:46:21.297744+00:00*